Exagen stock fell 3.19 percent after Q2 revenue hit USD 19.9 million

Published on 10/07/2026 at 06:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Exagen stock fell 3.19 percent to USD 8.19 on October 6, 2026, while Q2 revenue reached USD 19.9 million. Guidance rose to USD 72 million-USD 75 million.

XGN, US30068X1037, Illustration mit AI erstellt.

Exagen Inc. stock (ISIN US30068X1037) fell 3.19 percent to USD 8.19 on Nasdaq on October 6, 2026, while the company enters its next reporting cycle after a record second quarter. The Q2 figures included revenue of USD 19.9 million, a 16 percent year-over-year increase, and raised fiscal 2026 revenue guidance of USD 72 million-USD 75 million.

Revenue reaches a quarterly record

According to Benzinga, Exagen reported record Q2 2026 revenue of USD 19.9 million, up 16 percent from the same quarter a year earlier. The company also reported adjusted EBITDA loss of USD 0.1 million, compared with USD 1.7 million in Q2 2025.

The improvement reached the operating line while gross margin exceeded 61 percent in Q2 2026. Exagen's finance data show GAAP net loss of USD 3.196 million and diluted GAAP loss of USD 0.13 per share for the quarter ended June 30, 2026.

Guidance points to higher scale

Benzinga reported that management lifted fiscal 2026 revenue guidance to USD 72 million-USD 75 million from USD 70 million-USD 73 million. The midpoint therefore rose from USD 71.5 million to USD 73.5 million, a USD 2 million increase.

The business drivers are visible in the operating metrics. AVISE CTD test volume reached nearly 39,000 tests in Q2 2026, up 11 percent year over year, while trailing twelve-month average selling price rose to USD 446, an increase of USD 18 per test or 4 percent.

Exagen's investor-relations materials describe AVISE as a portfolio of autoimmune diagnostic products built around its proprietary CB-CAP technology and aimed at differential diagnosis and monitoring of diseases including lupus and rheumatoid arthritis. The company also expects its Myositis offering to reach commercialization in early 2027, according to the Exagen investor-relations page.

Consensus target stays above the stock

According to MarketBeat on September 21, 2026, nine analysts held a Moderate Buy consensus for Exagen, with an average twelve-month price target of USD 9.625. Against the USD 8.19 Nasdaq price on October 6, 2026, that target lies 17.5 percent above the stock.

Market data put Exagen's market capitalization at USD 197.9 million on October 6, 2026. The same session's volume was 271,751 shares, while the 52-week range extended from USD 2.59 to USD 12.23, leaving the stock USD 4.04 below its yearly high.

Exagen stock trades below its yearly high

Exagen stock was last at USD 8.19 on Nasdaq on October 6, 2026 at 4:00 p.m. ET, down USD 0.27 from the prior close of USD 8.46. The combination of higher guidance and a still-negative GAAP result leaves revenue conversion and the path to adjusted EBITDA breakeven as the key operating measures for the next update.